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Organotypic hippocampal slice culturesToll-like receptors (TLRs), which have been implicated in various neuroinﬂammatory responses, are
thought to act in defense mechanisms by inhibiting neuronal cell death in Alzheimer’s disease. In this
study, we evaluated the effects of TLR2 on amyloid beta peptide 25–35 (Ab25–35)-induced neuronal cell
death, synaptic dysfunction, and microglial activation in organotypic hippocampal slice cultures (OHSCs)
from wild-type (WT) C57BL/6 mice and TLR2-knockout (KO) mice. In WT mice, Ab25–35 induced b-amy-
loid aggregation and surrounding TLR2 expression. And, propidium iodide (PI) uptake, which is a measure
of cell death, increased in a dose-dependent manner in slices with Ab25–35 treatment. In the Ab25–35-trea-
ted TLR2-KO OHSCs, the PI uptake was signiﬁcantly attenuated to the control level, indicating that the
cells were less susceptible to Ab25–35-induced neuronal toxicity. In the ultrastructural analysis, nuclear
shrinkage, slightly swollen mitochondria, and degraded organelles were detected in the Ab25–35-treated
slices from WT mice but not in the Ab25–35-treated slices from TLR2-KO, suggesting the resistance of
TLR2-KO to Ab25–35-induced neurotoxicity. In Ab25–35-treated OHSCs of WT mice, the levels of phosphor-
ylated tau were increased and the levels of synaptophysin were decreased in a dose-dependent manner,
but they were not changed in OHSCs of TLR2-KO mice. In WT mice, Ab25–35 increased total protein level
and immunoreactivity of Iba-1, which was colocalized with TLR2. However, there were no signiﬁcant
changes in the slices of Ab25–35-treated TLR2-KO mice. These results suggested that TLR2 may play a role
in Ab25–35-induced neuronal cell loss and synaptic dysfunction through the activation of microglia in
OHSCs.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
The disruption of neuronal cell connections results in synaptic
loss and damage, which in turn leads to the characteristic symp-
toms of dementia (Gleichmann and Mattson, 2010; Selkoe, 2002).
The most common cause of dementia in the elderly is Alzheimer’s
disease (AD), which is clinically characterized by memory loss and
cognitive dysfunction (Hardy and Selkoe, 2002), and it is patholog-
ically characterized by the loss of neurons, intracellular neuroﬁ-brillary tangles, and extracellular deposits of b amyloid plaques
(Schrag et al., 2008; Selkoe and Schenk, 2003; Takahashi et al.,
2010). Although amyloid beta peptide (Ab) is well known as the
main cause of neuronal cell death (Baskys and Adamchik, 2001;
Cavallucci et al., 2012; Kreutz et al., 2011; Kudo et al., 2012; Suh
et al., 2008), the exact mechanism is not completely understood.
The deposition of Ab, particularly in the ﬁbrillar form, is closely
associated with inﬂammatory responses (Tahara et al., 2006; Udan
et al., 2008). Ab deposits activate microglia, the principal immune
effector cells of the brain, and initiate a proinﬂammatory cascade
that results in the release of potentially cytotoxic molecules, cyto-
kines, and other related compounds (Liu et al., 2012; Neher et al.,
2011; Richard et al., 2008).
Toll-like receptors (TLRs) are a family of pattern recognition
receptors and have functions in innate immune recognition.
Activated TLRs lead to intracellular signal transduction cascades,
which upregulate the expression of proinﬂammatory cytokines,
chemokines, nitric oxide synthase, and other anti-microbial pep-
tides that directly destroy microbial pathogens (Covacu et al.,
2009; Han and Ulevitch, 2005).
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ulate immune responses through the activation of microglia when
neurons are exposed to brain injury (Hoffmann et al., 2007; Hong
et al., 2010; Vollmar et al., 2010). Many subtypes of TLRs (TLR2,
TLR3, TLR4, and TLR9) are detected in the central nervous system,
including neurons, astrocytes, and microglia (Hamanaka and Hara,
2011; Hoffmann et al., 2007; Lafon et al., 2006; Lotz et al., 2005).
The activation of TLR2 results in increased proinﬂammatory
cytokines in response to various types of neuronal damage, includ-
ing brain ischemia (Hamanaka and Hara, 2011; Lv et al., 2011;
Ziegler et al., 2011), Wallerian degeneration (Boivin et al., 2007),
multiple sclerosis (Hanafy and Sloane, 2011), and spinal cord in-
jury (Hoffmann et al., 2007; Kim et al., 2007). The inhibition of
TLR2 promotes neuronal survival in focal cerebral ischemia
(Ziegler et al., 2011), and kainic acid-induced neurotoxicity and
microglial activation were compromised in TLR2-knockout (KO)
mice (Hong et al., 2010), suggesting TLR2’s role in neurotoxicity.
TLRs are also involved in the clearance of Ab deposits in AD
conditions (Tahara et al., 2006), and the infusion of Ab1–42 into
the hippocampus induced TLR2 expression (Richard et al., 2008).
Fibrillar Ab activates microglia through the TLR2 signaling path-
way, which mediates the increased cellular uptake of Ab and has
a pathophysiological signiﬁcance (Jana et al., 2008). Although there
are many reports about Ab induced neurotoxicity, the role of TLR2
in Ab-induced neuronal cell death is still unclear.
Because TLR2 is expressed in other immune cells in vivo, it is
still possible that the modiﬁcation of Ab-induced neurotoxicity in
TLR2-KO mice is due to TLR2 ablation in other immune cells, rather
than microglia. Therefore, in this study, we investigated the roles of
TLR2 through the microglial activation of Ab25–35-induced neuro-
toxicity in organotypic hippocampal slice cultures (OHSCs).2. Materials and methods
2.1. Animals
TLR2-KO mice were generously donated by Dr. Sung Joong Lee.
All surgical and experimental procedures were reviewed and
approved by the Institutional Animal Care and Use Committee
(IACUC) of Ewha Womans University.Fig. 1. Presence of b-amyloid aggregation and increase of TLR2 in wild-type (WT) mice wi
with Thioﬂavin S were detected in Ab25–35 treatment in compare to control. (B) Immuno
Ab25–35 treatment in compare to control. TLR2 expression was usually found near b-amy
level of TLR2 (90–100 kDa) was increased after Ab25–35 treatment. The quantitative anal
densitometric analysis was based on b-actin levels. TLR2 value was shown as the means ±
with (⁄) [p < 0.01, one-way analysis of variance (ANOVA) on ranks followed by Fisher’s P2.2. Preparation of OHSCs
The OHSCs were prepared, as previously described (Jung et al.,
2012; Suh et al., 2008), from the hippocampus of 8-day-old
TLR2-KO mice and C57BL/6 mice, which were used as the
wild-type (WT) controls. They were dissected and cut at a 400-
lm thickness with a McIlwain tissue chopper (The Mickle Labora-
tory Engineering Co., Ltd., Surrey, UK). The medium was changed
twice weekly for 2 weeks.
2.3. Treatment of OHSCs with Ab25–35
Ab25–35 is shorter than Ab1–42, but it is sufﬁcient to cause neuro-
toxicity similar to Ab1–42 (Chen et al., 2013; Frozza et al., 2009; Suh
et al., 2008). Ab25–35 (Sigma–Aldrich Co., St. Louis, MO) was
dissolved in sterile deionized water to give a stock solution with
a concentration of 1 mM, and was then incubated at 37 C for
24 h in order to obtain the aggregated ﬁbrillar form. The ﬁnal
concentrations (10, 25, and 50 lM) of the Ab25–35 solutions were
applied to culture medium for 72 h.
2.4. Thioﬂavin S (ThS) staining
To detect amyloid plaques, modiﬁed ThS staining (Lee et al.,
2002) was performed in the OHSCs of WT mice. After ﬁxation with
4% paraformaldehyde, the slices were stained with 0.5% thioﬂavin S
(Sigma–Aldrich Co.) for 8 min in dark room and washed three
times with 80% ethanol for 2 min, and washed twice with 95% eth-
anol for 3 min, and then washed with distilled water before block-
ing. The slices were mounted with vectashield including DAPI
(Vector Lab. Inc., Burlingame, CA).
2.5. Measurement of propidium iodide (PI) uptake
The extent of cell death was assessed with the ﬂuorescent
exclusion dye PI. PI (2 lg/mL) was added to the culture medium
and incubated in the dark for 2 h at 37 C. After washing with
phosphate-buffered saline (PBS), images were obtained with an in-
verted ﬂuorescence microscope (Zeiss Axiovert 200; Carl Zeiss
Microscopy GmbH, Göttingen, Germany). The image intensity
was analyzed using the AxioVision version 4.7.1.0 program
(Imaging Solutions GmbH, Munich, Germany). For the quantiﬁca-th amyloid beta peptide 25–35 (Ab25–35) treatment. (A) The amyloid plaques stained
ﬂuorescence staining for Ab and TLR2. The b-amyloid aggregation was increased by
loid aggregation. Scale bar = 20 lm. (C) Western blot analysis for TLR2. The protein
ysis of TLR2 (n = 3) was performed with the Multi Gauge version 3.0 program. The
standard error of the mean. Signiﬁcant differences from control values are indicated
LSD method].
Fig. 2. Detection of neuronal cell death by propidium iodide (PI) uptake in WT and Toll-like receptor 2-knockout (TLR2-KO) mice with Ab25–35 treatment. (A) Representative
images of PI uptake in WT and TLR2-KO mice. The PI staining dramatically increased in all selected areas, including CA1 (B) and CA3 (C), in a dose-dependent manner in WT,
but not in the TLR2-KO group. PI value was shown as the means ± standard error of the mean. Signiﬁcant differences from control values are indicated with (⁄) and from each
group are indicated with (+) [p < 0.01, one-way analysis of variance (ANOVA) on ranks followed by Fisher’s PLSD method]. Scale bar = 200 lm.
820 E.C. Suh et al. / Neurochemistry International 63 (2013) 818–825tion, a region of interest was selected from the bright-ﬁeld images
of each slice. Relative cell death was calculated as previously dem-
onstrated (Jung et al., 2004; Suh et al., 2008).2.6. Ultrastructural analysis with transmission electron microscopy
The slices were ﬁxed with 2.5% glutaraldehyde and 2% parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.4). The slices were
postﬁxed in 1% osmium tetroxide, dehydrated gradually in ethanol,
and embedded with Epon 812. Semithin sections (100 nm) were
cut from tissue blocks and stained with 0.5% toluidine blue. TheFig. 3. The ultrastructural changes in the CA3 area revealed by transmission electron mic
were observed between control slices from WT and TLR2-KO. After Ab25–35 treatment
mitochondria, and abnormally arranged microtubules compared to the control. The dege
However, there were no speciﬁc changes in the slices of TLR2-KO mice, after Ab25–35 tre
rough endoplasmic reticulum, Scale bar = 2 lm.)most superﬁcial stratum lucidum and mossy ﬁber layers were
identiﬁed by the meningeal tissue for subsequent thin sectioning.
The ultrathin sections were stained with 0.25% lead citrate and
2% uranyl acetate in 50% methanol and observed with an electron
microscope (Hitachi H7650; Hitachi High-Technologies Corpora-
tion, Tokyo, Japan).2.7. Protein extraction and Western blot analysis
The slices were lysed in 50 lL of ice-cold lysis buffer (50 mM
Tris–HCl, 1% IGEPAL, 0.25% deoxycholic acid, 150 mM NaCl, 1 mMroscopy in WT and TLR2-KO mice with Ab25–35 treatment. No signiﬁcant differences
, WT slices had nuclear shrinkage, loss of membrane continuity, slightly swollen
nerating neuronal cell bodies and processes were detected in Ab25–35-treated slices.
atment. (N: nucleus, G: Golgi apparatus, M: microtubules, mt: mitochondrion, RER:
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inhibitor (Roche Diagnostics GmbH, Penzberg, Germany) and were
brieﬂy sonicated. Samples were boiled for 5 min, and 20 lg of pro-
tein was electrophoresed on a 12% sodium dodecyl sulfate–poly-
acrylamide gel. The proteins were transferred onto blotting
membranes (0.45 mm, polyvinylidene diﬂuoride, Millipore, Bille-
rica, MA). The membranes were blocked for 1 h with Tris-buffered
saline Tween (TBST; 20 nM Tris, 500 nM NaCl, and 0.05% Tween 20)
containing 10% skim milk and were probed overnight at 4 C with
anti-TLR2 (rabbit polyclonal IgG, 1:500; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), anti- p-tau(Ser262) (rabbit polyclonal IgG,
1:200; Santa Cruz Biotechnology, Inc.), anti-synaptophysin (mouse
monoclonal IgG1, 1:1,000; Millipore, Billerica, MA), or anti-Iba1
(rabbit polyclonal, 1:500; Wako Pure Chemical Industries, Ltd.,
Osaka, Japan). Immunoreactive bands were visualized with a
luminescent image analyzer (LAS 3000 imaging system; Fujiﬁlm
Corporation, Tokyo, Japan) using a chemiluminescence reagent
(Santa Cruz Biotechnology, Inc.). Densitometric data were obtained
with the Multi Gauge version 3.0 image analysis software (Fujiﬁlm
Corporation, Tokyo, Japan). For a loading control, membranes were
stripped and reprobed with an anti-actin antibody (1:1,000; Santa
Cruz Biotechnology, Inc.). Total protein levels for p-tau (Ser262),Fig. 4. Hyperphosphrylation of tau after Ab25–35 treatment in OHSCs. (A) Western blo
treatment. The levels of p-tau protein (46–68 kDa) increased in a dose-dependent man
quantitative analysis of p-tau (n = 5) was performed with the Multi Gauge version 3.0
shown as the means ± standard error of the mean. Signiﬁcant differences from control va
followed by Fisher’s PLSD method]. (B) Immunoﬂuorescence staining of NeuN and p-t
damaged neurons with less NeuN immunoreactivity. Scale bar = 20 lm.TLR2, Iba-1, or synaptophysin were measured in the aliquots from
the same slice sample and were normalized to actin.
2.8. Immunoﬂuorescence staining
The slices were ﬁxed for 24 h with 4% paraformaldehyde
(Merck, Darmstadt, Germany) in 0.1 M phosphate buffer and then
incubated at room temperature for 1 h in blocking solution con-
taining 0.2% Triton X-100 in 10% bovine serum albumin in PBS.
The slices were incubated for 24 h at 4 C with anti-b-amyloid
(mouse monoclonal IgG1, 1:500; Santa Cruz Biotechnology, Inc.),
anti-TLR2 (mouse monoclonal IgG2a, 1:500; eBioscience), anti-
TLR2 (rabbit polyclonal IgG, 1:500; Santa Cruz Biotechnology,
nc.), anti-NeuN (mouse monoclonal IgG1, 1:1,000; Millipore),
anti-p-tau (Ser262) (rabbit polyclonal IgG, 1:200; Santa Cruz Bio-
technology, Inc.), or anti-Iba1 (rabbit polyclonal, 1:500; Wako Pure
Chemical Industries, Ltd.). After 3 washes with 3% bovine serum
albumin in PBS, anti-rabbit or anti-mouse secondary antibodies
that were conjugated to Alexa ﬂuor 488 goat anti-rabbit IgG
(1:1,000; Life Technologies, Grand Island, NY) or Alexa ﬂuor 555
goat anti-mouse IgG (1:1,000; Life Technologies) were applied.
The slices were mounted with Elvanol mounting mediumt analysis of p-tau (ser 262) in the slices of WT and TLR2-KO mice with Ab25–35
ner after Ab25–35 treatment, whereas they were not changed in TLR2-KO mice. The
program. The densitometric analysis was based on b-actin levels. p-tau value was
lues are indicated with (⁄) [p < 0.01, one-way analysis of variance (ANOVA) on ranks
au (ser 262) in the slices of WT. The immunoreactivity of p-tau was observed in
822 E.C. Suh et al. / Neurochemistry International 63 (2013) 818–825(Waterborne, Inc., New Orleans, LA), and images were obtained
with a confocal microscope (Zeiss LSM 510; Carl Zeiss Microscopy
GmbH, Jena, Germany).
2.9. Data analysis
The results are represented as the mean ± standard error of the
mean (SEM). The data were analyzed with analysis of variance (AN-
OVA) tests using Statview version 5 software (SAS Institute, Inc.,
Cary, NC). A Fisher’s post hoc test was used to determine the means
thatwere signiﬁcantly different from the controlmean. p values that
were less than 0.05 were considered to be statistically signiﬁcant.3. Results
3.1. Ab25–35 increased b-amyloid aggregation and TLR2 in the OHSCs of
WT mice
To conﬁrm Ab25–35-induced neurotoxicity model, ThS staining
or immunoﬂuorescence staining for b-amyloid were performed.
After Ab25–35-treatment to the OHSCs of WT mice, amyloid plaques
stained with ThS and b-amyloid aggregation were remarkably in-
creased, indicating Ab25–35-induced neurotoxicity model (Fig. 1A
& B).
Since the deposition of b-amyloid aggregation in AD is related
to neuroinﬂammatory response such as TLRs (Chen et al., 2006;
Bolmont et al., 2008; Reed-Geaghan et al., 2010), the relationship
between TLR2 activation and deposition of b-amyloid in
Ab25–35-induced neurotoxicity model was evaluated. The total
protein level and immunoﬂuorescence for TLR2 after treatment
of Ab25–35 were signiﬁcantly increased (Fig. 1B & C), and TLR2
expression was usually found near b-amyloid aggregation
(Fig. 1B), suggesting Ab25–35-induced local neuroinﬂammation.
3.2. Ab25–35-induced neuronal cell death was reduced in the OHSCs of
TLR2-KO mice
To examine the effect of TLR2 on the Ab25–35-induced neuronal
toxicity, PI uptake was analyzed quantitatively. WithoutFig. 5. Western blot analysis of synaptophysin in the slices of WT and TLR2-KO mice w
marker protein, synaptophysin, (38 kDa) decreased in a dose-dependent manner in W
synaptophysin (n = 3) was performed with the Multi Gauge version 3.0 program. The den
the means ± standard error of the mean. Signiﬁcant differences from control values are in
by Fisher’s PLSD method].Ab25–35, cells with PI uptake were hardly observed in the cultured
hippocampal slices from both WT and TLR2-KO mice (Fig. 2A). WT
OHSCs that received Ab25–35 treatment for 3 days had signiﬁcantly
increased PI intensity that was concentration-dependent (10, 25,
and 50 lM; Fig. 2A) in both CA1 (37.24 ± 8.34, 42.34 ± 8.34, and
52.20 ± 8.07, respectively; Fig. 2B) and CA3 (15.20 ± 13.15,
33.14 ± 6.1, and 33.04 ± 6.77, respectively; Fig. 2C) areas. In the
Ab25–35-treated TLR2-KO OHSCs, the PI uptake was signiﬁcantly
attenuated to the control level (Fig. 2), indicating that neurons in
OHSCs from TLR2-KO mice are less susceptible to Ab25–35-induced
neuronal toxicity.
3.3. Ab25–35-induced changes in ultrastructure were less vulnerable in
the OHSCs of TLR2-KO mice
In the control OHSCs from both WT and TLR2-KO mice, the nu-
clei were clearly observed, mitochondria were abundant, and other
organelles were well distributed. Microtubules in the axons were
densely packed and had parallel arrangements. No signiﬁcant dif-
ferences were observed between WT and TLR2-KO. In the Ab25–
35-treated OHSCs from WT mice, the nucleus has shrunk, the plas-
ma membrane continuity was lost, and numerous vacuolations in
the cytoplasm were observed. Mitochondria were slightly swollen
and abnormally developed. Microtubules showed widened inter-
vals and unparallel arrangements. In the Ab25–35-treated OHSC
from TLR2-KO mice, the nucleus and other organelles, including
mitochondria, rough endoplasmic reticulum, and microtubules,
appeared quite normal (Fig. 3). Ultrastructural changes were not
speciﬁcally detected, suggesting the resistance of TLR2-KO to
Ab25–35-induced neurotoxicity.
3.4. Ab25–35-induced expression of phosphorylated tau was not
increased in the OHSCs of TLR2-KO mice
The hyperphosphorylation of tau is known to be involved in im-
paired neuronal function in AD (Johansson et al., 2006; Metcalfe
and Figueiredo-Pereira, 2010; Obulesu et al., 2011). To clarify the
relationship among Ab25–35-induced neuronal cell death, the phos-
phorylation of tau, and TLR2, western blot analysis of p-tau (Ser
262) was performed. The total protein level of phosphorylatedith Ab25–35 treatment. After Ab25–35 treatment, the protein levels of a presynaptic
T mice, but there were no changes in TLR2-KO mice. The quantitative analysis of
sitometric analysis was based on b-actin levels. Synaptophysin value was shown as
dicated with (⁄) [p < 0.01, one-way analysis of variance (ANOVA) on ranks followed
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in Ab25–35-treated OHSCs of WT mice (112.71 ± 11.93,
135.21 ± 2.72, and 150.16 ± 10.04, respectively), but they were
not changed in the OHSCs of TLR2-KO mice (Fig. 4A).
In immunoﬂuorescence analysis for the OHSCs of WT mice,
Ab25–35 induced the hyperphosphorylation of tau mostly in
damaged neurons which expressed less NeuN immunoreactivity
(Fig. 4B).
3.5. Ab25–35-induced reduction of synaptophysin was not found in
OHSCs of TLR2-KO mice
To determine the role of TLR2 in Ab25–35-induced synaptic fail-
ure, western blot analysis of synaptophysin was used. The levels of
synaptophysin were decreased in a dose-dependent manner (10,
25, and 50 lM) in Ab25–35-treated OHSCs of WT mice
(84.24 ± 7.89, 73.29 ± 11.74, and 61.55 ± 9.46, respectively). In con-
trast, the levels of synaptophysin were not decreased in OHSCs of
TLR2-KO mice (Fig. 5).
3.6. Ab25–35-induced microglial activation was reduced in the OHSCs of
TLR2-KO mice
In order to investigate the role of TLR2 in the microglial activa-
tion that is induced by Ab25–35, we performed western blot analysisFig. 6. Activation of microglia through TLR2 after Ab25–35 treatment in OHSCs. (A) Immu
After Ab25–35 treatment in WT mice, Iba-1 immunoreactivity increased in a dose-depend
there was no change in TLR2-KO mice. The quanatitative analysis of Iba-1-positive cells (
from control values are indicated with (⁄) [p < 0.01, one-way analysis of variance (ANOV
analysis of Iba-1 from WT and TLR2-KO mice with Ab25–35 treatment. After 25 lM of Ab2
TLR2-KO mice. The quantitative analysis of Iba-1 (n = 4) was performed with the Multi G
Iba-1 value was shown as the means ± standard error of the mean. Signiﬁcant difference
(ANOVA) on ranks followed by Fisher’s PLSD method]. (C) Immunoﬂuorescence staining
speciﬁcally co-localized with TLR2 after Ab25–35 treatment. Scale bar = 20 lm.and immunoﬂuorescence staining for Iba-1. The total protein level
of Iba-1 in the OHSCs of WT mice was signiﬁcantly increased after
treatment with 25 lM Ab25–35 (140 ± 10.83). There were no differ-
ences in the protein levels of Iba-1 between control and Ab25–35-
treated TLR2-KO mice (Fig. 6B).
In the OHSCs from WT mice, the number of Iba-1-positive
microglia is increased in a dose-dependent manner (10, 25, and
50 lM) in the Ab25–35-treated CA3 area (25.23 ± 3.74,
22.35 ± 0.65, and 29.93 ± 0.99, respectively) compared to WT
(14.23 ± 2.53). The morphology of Iba-1–positive cells in OHSCs
of WT mice showed thicker and longer processes with Ab25–35
treatment, suggesting activation, and this response was dose-
dependent (Fig. 6A). These increased Iba-1 immunoreactivity by
Ab25–35 treatment in OHSCs of WT mice was colocalized with
TLR2 (Fig. 6C). The Ab25–35-induced Iba-1 activation was signiﬁ-
cantly decreased in OHSCs of TLR2-KO mice compared to that of
WT mice according to the quantiﬁcation of the immunoreactivity
of Iba-1 (Fig. 6A).4. Discussion
In this study, we demonstrated that TLR2 contributes to
Ab25–35-induced hippocampal neuronal cell death.noﬂuorescence staining for Iba-1 in WT and TLR2-KO mice with Ab25–35 treatment.
ent manner and Iba-1–positive cells showed thicker and longer processes, whereas
n = 5) was shown as the means ± standard error of the mean. Signiﬁcant differences
A) on ranks followed by Fisher’s PLSD method]. Scale bar = 20 lm. (B) Western blot
5–35 treatment, the protein level of Iba-1 (17 kDa) increased in WT mice, but not in
auge version 3.0 program. The densitometric analysis was based on b-actin levels.
s from control values are indicated with (⁄) [p < 0.01, one-way analysis of variance
for Iba-1 and TLR2 in WT mice after Ab25–35 treatment. Iba-1 immunoreactivity was
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cellular events, including apoptotic or necrotic cell death (Ishige
et al., 2007; Kreutz et al., 2011; Suh et al., 2008). Fig. 1 showed that
amyloid aggregates were present in CA3 area after Ab25–35 treat-
ment in OHSCs of WT mice, suggesting that a short 25–35 of b-
amyloid is sufﬁcient to cause Ab effects. Additionally, there are
many previous studies that have demonstrated the involvement
of neuroinﬂammation in AD, including proinﬂammatory mediators
(Akiyama et al., 2000), microglial activation surrounding Ab pla-
ques (Bolmont et al., 2008; Bornemann et al., 2001), and increased
TLR expression (Fassbender et al., 2004; Letiembre et al., 2007;
Walter et al., 2007). Fig. 1 also showed that TLR2 expression was
increased surrounding b-amyloid aggregation, suggesting
Ab25–35-induced neuroinﬂammation. However, the role of TLR2 in
Ab-induced neuronal cell death is still unclear. Because TLR2 is
highly expressed in other immune cells of the whole body, it is still
possible that the effect of TLR2 KO is due to immune cells other
than microglia. Therefore, we chose an ex vivo AD model using
the OHSCs of TLR2-KO mice.
Our ﬁndings show that increased PI uptake, ultrastructural
damages including mitochondrial abnormality, and hyperphosph-
orylation of tau in the damaged neurons after Ab25–35 treatment
are signiﬁcantly attenuated in the OHSCs of TLR2-KO mice com-
pared to controls. Ab can cause mitochondrial dysfunction (Hardy
and Selkoe, 2002; Johansson et al., 2006; Obulesu et al., 2011;
Rapoport et al., 2002; Reddy, 2011) and hyperphosphorylation
and aggregation of tau (Johansson et al., 2006; Obulesu et al.,
2011; Ott et al., 2011; Reddy, 2011; Schrag et al., 2008) in neurons
with neurite degeneration and microtubule disintegration. On the
basis of these results, we suggest that the hyperphosphorylation
of tau may be related to increase of TLR2 during Ab25–35-induced
neurotoxicity.
Although a number of studies that focused on the synaptic
impairment in AD have been reported, the current understanding
is not sufﬁcient to explain the relationship among Ab, TLR2, and
synaptic function. Ab accumulation reduced the synapse density
of cortical and hippocampal neurons (Selkoe, 2002), and the
expression of presynaptic proteins was decreased by Ab25–35-in-
duced hippocampal neuronal cell death (Costello et al., 2011; Suh
et al., 2008). In this study, the level of synaptophysin, which is a
marker of a presynaptic protein, was decreased by Ab25–35 in a
dose-dependent manner in WT mice but not in TLR2-KO mice.
These results suggest the possibility that TLR2 may play a role in
Ab25–35-induced synaptic dysfunction.
Microglia play a role in the pathogenesis of AD (Akiyama et al.,
2000; Neher et al., 2011; Wyss-Coray, 2006). In neurons over-
expressing amyloid precursor protein, microglia are activated and
recruited to Ab deposits (Bolmont et al., 2008; Meyer-Luehmann
et al., 2008; Tahara et al., 2006), and Ab25–35 causes microglia-
dependent neuronal loss (Vollmar et al., 2010). Microglia constitu-
tively express TLR2 (Bsibsi et al., 2002; Hanke and Kielian, 2011;
Olson and Miller, 2004), and TLRs play a role in Ab-inducedmicrog-
lial activation (Chen et al., 2006; Liu et al., 2012; Tahara et al.,
2006; Tang et al., 2007). Ab-triggered inﬂammatory activation is
reduced in TLR2-deﬁcient microglia (Jana et al., 2008), and TLR2
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Taking these results together, we conclude that TLR2 may play a
role in Ab25–35-induced neuronal cell loss and synaptic dysfunction
through the activation of microglia in OHSCs.References
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